z-logo
Premium
Double‐Blind Placebo‐Controlled Trial of Terazosin Effect on Blood Pressure and Urinary Output of Dopamine in Hypertensive Patients
Author(s) -
Romero E.,
Angeli M.,
Velasco M.,
Azar E.,
Bueno O.,
Lema G.,
Morales N.,
Nuchi Y.,
Rasines C.,
Wagner A.
Publication year - 1992
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/j.1552-4604.1992.tb03888.x
Subject(s) - terazosin , blood pressure , placebo , medicine , anesthesia , double blind , dopamine , urinary system , pharmacology , alternative medicine , pathology , hyperplasia
In a parallel, double‐blind study, 12 untreated hypertensive patients received terazosin (2–4 mg/day for 4 weeks), and 12 received placebo during the same period. Systolic and diastolic blood pressure decreased significantly in the terazosin group, from 150 ± 5.0 mmHg systolic and 99.6 ± 2.0 diastolic before treatment, to 134.0 ± 7.0 systolic and 85.6 ± 3.0 mmHg diastolic at week 4 of treatment. No significant blood pressure changes occurred in the placebo group. Blood pressure decrease showed a positive correlation (r = .62 and r = .52 for systolic and diastolic blood pressure, respectively) with the patient's age (P < .05). Total plasma cholesterol decreased 18% in the terazosin group (P < .05) and 9% in the placebo group (P > .05). Urinary dopamine excretion decreased significantly from 692.8 ± 180.0 to 330.5 ± 52.0 μg/24 hours in the terazosin group (P < .05) and showed a nonsignificant increase in the placebo group. Compared with 22 age‐ and sex‐matched healthy volunteers, urinary dopamine excretion in the hypertensive group before treatment was not statistically different (779.3 ± 83.1 μg/24 hours). Dopamine excretion was higher in untreated hypertensive men and in male healthy volunteers compared with women. The decrease of urinary dopamine excretion observed under terazosin treatment could be due to a decrease of kidney dopamine synthesis or release induced by blood pressure reduction, or secondarily to the blockade of kidney α 1 ‐receptors, modulating dopamine excretion. No significant changes were observed in urinary excretion of noradrenaline and adrenaline.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here